By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

LFB S.A. 

3, avenue des Tropiques
B.P. 305 - Les Ulis
Courtaboeuf   Cedex  91958  France
Phone: 33-0-1-69-827010 Fax: 33-0-1-69-071903


SEARCH JOBS








Company News
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015 11:08:44 AM
LFB S.A. Announces That First Patient Has Begun Treatment With New Coagulation Factor VIIa (Recombinant) In Global Phase 3 Clinical Trial In Hemophilia A And B With Inhibitors 5/14/2014 10:16:04 AM
LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B 3/3/2014 9:17:36 AM
LFB S.A.'s Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in the USA for Chronic Lymphocytic Leukemia 8/26/2010 8:14:08 AM
GTC Biotherapeutics (GTCB) Announces Conversion of LFB S.A.'s Preferred Stock into Common Shares and Provides a Portfolio Update 1/8/2010 10:20:41 AM
The French Biopharmaceutical Group LFB S.A. Has Announced the First-in-Man Injections of Its First Two Therapeutic Monoclonal Antibodies and the Filing of BLAs for a New-Generation Immunoglobulin and a Fibrinogen 2/10/2009 10:04:33 AM
//-->